CXS
Chemgenex Pharmaceut
- Short interest
- 0.00%
- −0.01 pp 30d
- as of 22 July 2011
- Reported shorts
- 2.2K
- Shares on issue
- 313.559M
No director trades found
Public-source evidence for this company, with industry drill-up links.
AI-generated research profile of Chemgenex Pharmaceut
Chemgenex Pharmaceuticals was an Australian biotechnology company focused on the development of small molecule therapeutics for cancer and other life-threatening diseases. Its primary asset was OMAPRO (omacetaxine mepesuccinate), a drug for chronic myeloid leukemia (CML). The company aimed to bring novel treatments through clinical trials to market, positioning itself in the niche area of hematological malignancies.